[X-ray diagnosis of carcinoma with special reference to breast carcinoma].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to W Schmerwitz.
Explore the source record for details and available documents.
In a total of 532 patients, Bilivistan and Endomirabil are compared in cholecystography regarding side effects and visualization. Endomirabil clearly demonstrates the advantage of better tolerance. It is shown that slow and constant injection leads to a decrease in the rate of adverse reactions and improvement of radiographic demonstration.
Two hepatotropic contrast media in 3 different concentrations each are administered to a total of 727 patients for infusion cholecystography. It is the purpose of the study to investigate frequency of adverse reactions and quality of radiographic demonstration. In regard to tolerance, Endomirabil clearly shows advantages over Biligram. The radiologic demonstration of Endomirabil is somewhat better than with Biligram. The frequency of adverse reactions shows to be influenced by the concentration of the contrast medium as well as time of infusion, which particularly applies to Endomirabil, while in regard to the quality of visualization, ni dependence on either concentration of infusion time could be demonstrated.
Cerebral angiography was performed in 501 patients with a new contrast medium. There was good contrast and the vessels were very well visualized. 15 patients (2,9%) had side effects. These were reversible; there were no persistent distrubances. These were almost exclusively seen in patients with vascular cerebral lesions.
Explore the source record for details and available documents.
Explore the source record for details and available documents.